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ABSTRACT
Genetic screens performed in model organisms
have helped identify key components of the RNA
interference (RNAi) pathway. Recessive genetic
screens have recently become feasible through the
use of mouse embryonic stem (ES) cells that are
Bloom’s syndrome protein (Blm) deficient. Here,
we developed and performed a recessive genetic
screen to identify components of the mammalian
RNAi pathway in Blm-deficient ES cells. Genome-
wide mutagenesis using a retroviral gene trap strat-
egy resulted in the isolation of putative homozygous
RNAi mutant cells. Candidate clones were con-
firmed by an independent RNAi-based reporter
assay and the causative gene trap integration site
was identified using molecular techniques. Our
screen identified multiple mutant cell lines of
Argonaute 2 (Ago2), a known essential component
of the RNAi pathway. This result demonstrates that
true RNAi components can be isolated by this
screening strategy. Furthermore, Ago2 homozygous
mutant ES cells provide a null genetic background
to perform mutational analyses of the Ago2 protein.
Using genetic rescue, we resolve an important con-
troversy regarding the role of two phenylalanine
residues in Ago2 activity.
INTRODUCTION
The RNA interference (RNAi) pathway is a highly con-
served, sequence-speciﬁc gene silencing pathway that func-
tions in most eukaryotes (1–5). In mammals, RNAi can be
triggered by 20–23nt double-stranded small interfering
RNAs (siRNAs) or by short hairpin RNAs (shRNAs);
shRNAs expressed from transgenes are produced by
RNA polymerase II/III in the nucleus (6,7) and then
exported from the nucleus via exportin-5 (3,8). In the cyto-
plasm, the RNAse III enzyme, Dicer, cleaves the shRNA
into an siRNA (1–3,5,9). The siRNA is then unwound
through an unknown mechanism and one strand of the
siRNA, the guide strand, is incorporated into an
Argonaute 2 (Ago2) containing RNA induced silencing
complex (RISC) that targets the complementary mRNA
for cleavage and degradation (3–5,10).
RNAi serves important functions in diverse biological
processes including development, diﬀerentiation, cell divi-
sion, apoptosis and defense against transposons and
viruses (1,2,5,10). A greater understanding of the RNAi
pathway will enhance our ability to more eﬀectively use
RNAi for genetic analyses and therapeutics (5,7). Our
knowledge of the RNAi mechanism and machinery has
been greatly increased through genetic, biochemical and
structural biology studies. Forward genetic screens in sev-
eral model organisms have been instrumental in uncover-
ing key players and roles of RNAi. For example,
Argonaute proteins, major RNAi components, were dis-
covered in genetic screens performed in Caenorhabditis
elegans (11). Argonautes were also identiﬁed in other for-
ward genetic screens for quelling in Neurospora crassa and
posttranscriptional gene silencing (PTGS) in Arabidopsis
thaliana, thus linking these three related pathways (12,13).
Other components of the C. elegans RNAi pathway,
RNA-dependent RNA polymerases (RdRPs) and RecQ
proteins, were also identiﬁed using forward genetic screens
(14–17). A screen performed in Drosophila demonstrated
that Dicer1 and Dicer2 serve distinct functions in the
miRNA and siRNA pathways, respectively (18).
Components identiﬁed in these genetic screens have
helped direct our analyses of RNAi in mammals and high-
lighted the fact that several species-speciﬁc diﬀerences
exist for this pathway (8). For instance RdRPs, important
components of plant and worm RNAi, have not been
found to play a role in RNAi in ﬂies or mammals
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C. elegans and N. Crassa, yet the mammalian homologs,
Werner and Bloom, are not involved in RNAi (19). Thus,
a screen for components of the RNAi pathway in a mam-
malian system has the potential to identify RNAi compo-
nents that may be unique to mammals.
One obstacle to performing a recessive genetic screen in
mammalian cells is the diploid nature of the genome,
which requires that any recessive mutation be rendered
homozygous in order to observe a mutant phenotype.
This challenge has recently been partially overcome by
the use of Bloom’s syndrome protein (Blm)-deﬁcient
mouse embryonic stem (ES) cells. The Bloom gene encodes
a homolog of the bacterial RecQ helicase and loss of this
gene leads to genome instability. An 18- to 27-fold higher
loss-of-heterozygosity (LOH) has been reported for Blm-
deﬁcient ES cells compared with wild-type ES cells (20,21).
Therefore, these cells cause heterozygous mutations to be
rendered homozygous at a much higher frequency. Several
pioneering studies have shown that Blm-deﬁcient ES cells
are amenable to forward phenotypic screens (21–23). A
screen performed in Blm-deﬁcient ES cells for mismatch
repair genes identiﬁed a novel component, Dnmt1 (22).
In this study, we took advantage of the high rate of
LOH that occurs in Blm-deﬁcient ES cells and developed
a drug resistance selection scheme to enrich for RNAi
mutants. Using retroviral gene traps, we successfully per-
formed a genome-wide screen for mammalian RNAi
mutants. This screen led to the isolation of multiple gene
trap mutants homozygous for Ago2. Thus, the identiﬁca-
tion of Ago2, a known essential component of RNAi,
validates the utility of our screening strategy. With
future improvements in insertion mutagenesis and an
increase of genomic coverage, our system has the potential
to identify other unknown components in the mammalian
RNAi pathway.
MATERIALS AND METHODS
Cellculture
Mouse ES cells were grown on feeder cells and maintained
in M15 as previously described (24). For the various drug
selections used in the study, the following drugs and con-
centrations were used: 250–350mg/ml Geneticin [G418
(Invitrogen)], 1 HAT Supplement (Invitrogen), 10mM
6-TG [6-thioguanine (Sigma)], 1–2mg/ml Puromycin
(Invivogen), 5–10mg/ml Blasticidin (Invitrogen).
Molecular cloning
To construct mouse U6-expressed shRNA vectors, the fol-
lowing oligos were phosphorylated, annealed and ligated
into a BbsI and XhoI digested mU6 vector. For Hprt
(hypoxanthine phosphoribosyl transferase), shRNA
Hprt5 sense: 50-TTT GCA CTG AAT AGA AAT AGT
GAT TTA TTA ATA TCA CTA TTT CTA TTC AGT
GCT TTT TC-30; shRNA Hprt5 antisense: 50-TCG AGA
AAA AGC ACT GAA TAG AAA TAG TGA TAT TAA
TAA ATC ACT ATT TCT ATT CAG TG-30. For ﬁreﬂy
luciferase (F-luc), shRNA luc1 sense: 50-TTT GTG TCG
CTC TGC CTC ATA GAA TTA TTA TTT CTA TGA
GGC AGA GCG ACA CTT TTT C-30 and shRNA luc1
antisense: 50-TCG AGA AAA AGT GTC GCT CTG
CCT CAT AGA AAT AAT AAT TCT ATG AGG
CAG AGC GAC A-30. For miRNA version of Has-mir-
30a, 2264: 50-TTT GCT GCA AAC ATC CTC GAC
TGG AAG TTA TTA ATC TTT CAG TCG GAT
GTT TGC AGC TTT TTC-30 and 2265: 50-TCG AGA
AAA AGC TGC AAA CAT CCG ACT GAA AGA
TTA ATA ACT TCC AGT CGA GGA TGT TTG
CAG-30.
To construct PGGV5 gene trap, a 110-bp loxP-contain-
ing unique DNA fragment was inserted between NheI and
SacI of PGGV2’s 30LTR. For PGGV6 and PGGV7, pPolII
was used as a shuttling vector to introduce the pPolII
promoter and SA2 into PGGV5. A segment of the
PGGV5 virus (the LacZ region between two Hpa sites
used for Southern analysis) was ampliﬁed and inserted
into the pPolII vector by HindIII and ClaI digestion to
create pPolII-Hpa. To construct PGGV6, the pPolII-Hpa
vector was cut with EcoRI and ClaI and the insert con-
taining the polII promoter and Hpa region was ligated
into EcoRI/ClaI digested PGGV5. To create the SA2,
the following oligos: 1961 (50-CGA TAG GGT TTC
CTT GAC AAT ATC ATA CTT ATC CTG TCC CTT
TTT TTT CCA CAG-30), 1962 (50-GAT CCT GTG GAA
AAA AAA GGG ACA GGA TAA GTA TGA TAT
TGT CAA GGA AAC CCT AT-30), were annealed, phos-
phorylated and ligated into pPolII-Hpa by BamHI/ClaI
digestion. To construct PGGV7, the pPolII-Hpa-SA2 was
cut with EcoRI and ClaI and the insert containing the
polII promoter-Hpa-SA2 was inserted into EcoRI/ClaI
digested PGGV5. All primers were obtained from
Integrated DNA Technologies.
Retroviral infection
To produce recombinant gene trap retroviruses, phoenix
cells were transfected with the gene trap retroviral con-
structs using the Calcium–Phosphate precipitation
method (Clontech) as described before (22). To infect
the reporter cell lines, ES cells were plated at 3 10
6
cells per 10cm plate and infected with retroviruses in the
presence of polybrene the following day.
Transfection ofdual luciferase reporters andeffectors
For transfection, ES cells were passaged at least twice
onto feeder-free gelatinized plates in M15 with LIF to
remove feeders. ES cells were plated at  1–2 10
5 cells
per well of a gelatinized 24 well plate. The following
day, cells were transfected using lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
For the shRNA cleavage assay the following constructs
were transfected: 0.1mgo fCMV-Fireﬂy luciferase, 0.02mg
of CMV-Renilla luciferase and 0.25mg of the eﬀector
DNA (U6-hprt or U6-luc1). For the miRNA assay, the
following constructs were transfected: 0.1mg CMV-
Fireﬂy-mir30x6, 0.02mg CMV-Renilla luciferase and
0.25mg of the eﬀector DNA (U6-hprt or U6-mir30A).
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The proviral junction fragment was identiﬁed through
Splinkerette PCR, described in (25). Genomic DNA was
digested with Sau3AI and ligated with splinkerette adap-
tors. The initial PCR was performed with primer 1092
50-GCT AGC TTG CCA AAC CTA CAG GTG G-30
and 1094 50-CGA AGA GTA ACC GTT GCT AGG
AGA GAC C-30 (for V2) or 1748 (50-TAG GTC ACT
CGA CCT GCA GAC C-30) and 1094 (for V5–V7). The
PCR product was diluted 1/1000 and used for a second
round of PCR with primers 1093 50-GCC AAA CCT ACA
GGT GGG GTC TTT-30and 1095 50-GTG GCT GAA
TGA GAC TGG TGT CGA C-30 (for V2) or 1749
50-TCG ACC TGC AGA CCA AGA TCG CT-30 and
1095 (for V5–V7). As a control, DNA from noninfected
reporter cells was used in the PCR. Speciﬁc PCR frag-
ments obtained only in the virus-infected mutant was
isolated, gel puriﬁed and either TA-cloned or directly
used for sequencing. All primers were obtained from
Integrated DNA Technologies.
Western, northern and Southern blot analysis
Antibodies against the following proteins were used
for western blotting: rabbit anti-Hprt polyclonal
antibody (Santa Cruz Biotechnology, Inc.), mouse mono-
clonal antibody against HA (12CA5) (Developmental
Studies Hybridoma Bank, DHSB) mouse monoclonal
anti-b-Tubulin antibody (DHSB) and rabbit monoclonal
antibody against Ago2 (Cell Signaling Technology).
For northern blotting of Hprt, a cDNA probe was PCR
ampliﬁed from the PGK-Hprt vector. For Southern blot
analyses, a 470bp fragment of LacZ sequence was labeled
with a-
32P-dCTP and used to detect proviral junction
fragments.
RESULTS
Development of arecessive genetic screen forRNAi mutants
in Blm-deficient ES cells
Previous studies indicated that, on average, one out of
every 5000 Blm-deﬁcient ES cells could become homozy-
gous for a mutation (20–22). Therefore, a genetic screen
performed in Blm-deﬁcient ES cells depends on a powerful
selection scheme to distinguish mutant cells from the rest
of the population. To establish a selection system for
RNAi mutants in Blm-deﬁcient ES cells, we chose Hprt
as the reporter gene because it allows for both positive and
negative selection. When stably expressed in the cells, Hprt
confers resistance to the drug HAT [hypoxanthine ami-
nopterin thymidine, HAT resistant (HAT
R)] and sensitiv-
ity to the drug 6-TG [6-thioguanine, 6-TG sensitive
(6-TG
S)]. By introducing an shRNA against the Hprt
gene, we can select for cells that silence the reporter gene
(becoming 6-TG resistant, 6-TG
R) through a working
RNAi pathway. More importantly, after mutagenesis the
Hprt reporter gene allows for positive selection (HAT
R)o f
cells that become RNAi deﬁcient.
We constructed our selection system using a Blm-
deﬁcient ES cell line, PGG5-4, that contains two copies
of the Hprt gene (Blm-deﬁcient Hprt
+/+ ES cells) (22).
This cell line was originally engineered from NM5 ES
cells that are Hprt-deﬁcient and Blm-deﬁcient. Two
copies of the PGK-Hprt minigene were sequentially tar-
geted at the mouse gdf7 locus in order to maintain homo-
zygosity for the Hprt gene required in an LOH-based
recessive genetic screen. The expression of Hprt in the
cells was conﬁrmed by drug selection with HAT and
6-TG (Figure 1A). We electroporated the cells with a
U6-promoter driven shRNA to silence the Hprt gene
through RNAi. The shRNA contained a puromycin
(puro) marker (puro::shRNA) to select for cells that
stably incorporated the transgene. Blm-deﬁcient cells
expressing the puro::shRNA eﬀectively silenced the Hprt
gene and the cells became puromycin resistant (puro
R),
HAT sensitive (HAT
S) and 6-TG
R (Figure 1B). These
reporter cell lines were expanded and used as the cell
lines for screening. Although our preliminary results
showed that one copy of shRNA was suﬃcient to
knock-down Hprt expression to an undetectable level,
the use of two independent shRNA transgenes can com-
pensate for the loss of a single transgene through mitotic
recombination. Therefore, reporter cell lines were created
that contained a second copy of Hprt shRNA, selectable
with zeocin (zeo::shRNA) in addition to the puro::shRNA
(not depicted in the diagram for simplicity). In the pres-
ence of Hprt shRNA, RNAi competent cells were selected
with 6-TG and then expanded to establish several cell lines
including 59, a8, c9 (containing puro::shRNA) 59Z4 and
59Z12 (containing both puro::shRNA and zeo::shRNA)
(Figure 1B).
We carried out our screen on several diﬀerent RNAi-
competent reporter cell lines (59, a8, c9, 59Z4 and 59Z12)
because the locations of the stably incorporated shRNAs
are unknown and the shRNAs might be expressed at dif-
ferent levels. The location of the shRNAs may also aﬀect
the probability of isolating an RNAi essential gene. For
example, if a retroviral integration occurs on the opposite
chromatid of the same chromosome in which the
puro::shRNA resides, a homozygous mutant for this inte-
gration site is less likely to be retained in our screen
because we preferentially select for the chromatid contain-
ing the puro::shRNA over the sister chromatid containing
the retroviral integration site.
To screen for RNAi mutant cells, we used a recombi-
nant retroviral gene trap strategy to mutagenize the repor-
ter cell lines. Retroviral gene trap mutagenesis has been
successfully used in recessive genetic screens performed in
Blm-deﬁcient ES cells (22,23). The major advantage of this
approach is the ability to use the gene trap provirus as a
molecular tag to identify the integration site. Integration
within a gene results in splicing of upstream exons to the
gene trap, and a polyadenylation signal in the gene trap
prematurely terminates the mRNA leading to a loss of
downstream exons (Figure 2A). The gene trap contains a
neomycin resistance marker to allow for Geneticin (G418)
selection of the stably integrated and expressed gene traps.
After integration, the gene trap contains two loxP sites,
and Cre-expression removes the gene trap leaving behind a
single long terminal repeat (LTR) in the locus. In some
cases, a gene trap event can be reverted after Cre excision
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with the endogenous locus.
To increase the genomic coverage of our screen, four
diﬀerent retroviral gene trap constructs were used
(Figure 2B). The PGGV2 retroviral gene trap vector was
used in previous recessive screens employing Blm-deﬁcient
ES cells (22,23). Several modiﬁcations to PGGV2 were
incorporated to create the following retroviral gene trap
vectors: PGGV5, PGGV6 and PGGV7 (Figure 2B).
PGGV5 contained a unique sequence inserted into the
LTR of PGGV2 to facilitate subsequent molecular cloning
of the integration. PGGV6 was a modiﬁed version of
PGGV5 containing an additional promoter to drive neo-
mycin resistance independent of the gene trap integration
site. PGGV7 was a modiﬁed version of PGGV6 with an
additional splice-acceptor site.
The reporter ES cell lines were infected with gene trap
retroviruses produced from a phoenix packaging cell line.
ES cells containing retroviral integrations that were active
gene traps were selected by G418 resistance (Figure 1C).
After distinct G418
R colonies had formed, the cells were
propagated twice to allow accumulation of homozygous
recessive mutations for the gene trap. The putative RNAi
mutant cells were selected with HAT for their ability to
Figure 1. A recessive genetic screen to isolate RNAi mutants in Blm-deﬁcient ES cells. The screen is diagrammed on the left and the drug resistance
phenotype of the cells is shown on the right. Viable ES cells appear dark blue when stained with methylene blue. (A) Blm
 /  Hprt
+/+ cells are HAT
R
and 6-TG
S.( B) After the addition of a puromycin-linked U6-shRNA-Hprt to silence the Hprt gene, cells become HAT
S and 6-TG
R.( C) Gene trap
mutagenesis generates mutations in the cells and can be selected with the drug G418. (D) The Blm-deﬁcient gene trapped ES cells accumulate
homozygous gene trap mutations. Mutations that inactivate the RNAi pathway lead to Hprt expression and these cells are HAT
R and Puro
R.
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R colonies were also selected
with puromycin to ensure that the puro::shRNA was
retained (Figure 1D). For PGGV2 and PGGV5, we cumu-
latively screened 80000 gene trap clones and for PGGV6
and PGGV7, we cumulatively screened 80000 gene trap
clones. For each G418
R clone, on average we screened
10000–40000 cells. Through this drug selection strategy,
we successfully isolated HAT
R putative RNAi mutant
ES cells.
Validation of RNAi mutants
We initially performed three assays to eliminate false posi-
tives and facilitate analysis of unique mutants. First, to
verify the drug-resistance proﬁle, colonies were transferred
to 96-well plates and replica plated for selection by HAT,
puro and G418 (Figure 3A). RNA and protein samples
from mutant clones that passed all drug resistance tests
were collected for further analyses. Second, we identiﬁed
unique gene trap events among candidate clones isolated
from the same plate. The process of expanding the gene-
trapped cells to generate homozygous mutations could
potentially result in identical mutant clones being isolated
multiple times. To avoid redundant analysis of identical
mutant clones, a Southern blot was performed on clones
isolated from the same plate. Genomic DNA was digested
with EcoRI, which cuts once in the provirus and then
hybridized with a probe for a unique region of the gene
trap (Figure 3B). Southern blot analyses revealed that
clones isolated oﬀ the same plate contained a similar pro-
viral–host genome junction fragment based on size, most
likely caused by daughter clones arising from passaging
(Figure 3B). In addition, Southern blot analyses revealed a
single band for the majority of the clones, which veriﬁed
that the retroviral gene trap did not integrate more than
once in the genome. Lastly, Hprt expression in the mutant
clones was examined by northern blot and western blot to
conﬁrm that the Hprt gene was not being silenced. Hprt
expression was negligible in reporter cell lines containing
the puro::shRNA but was re-expressed in the gene trap
mutant clones (Figure 3C).
Alternative reasons could account for the Hprt expres-
sion in the isolated HAT
R clones. For instance, a recom-
bination event could result in loss of the shRNA while
still retaining the purmoycin marker. To eliminate false
positives, we performed a secondary functional assay to
conﬁrm the RNAi mutant phenotype of the isolated
clones. A F-luc reporter was used to measure the repres-
sion by shRNA against F-luc. Renilla luciferase (R-luc)
served as an internal control for the transfection eﬃciency.
Reporter cell lines were transfected with F-luc, R-luc and
Figure 2. Diagram of retroviral gene trap constructs. (A) Schematic of how gene traps create mutations after integration. As an example, integration
of a proviral gene trap between exons 1 and 2 leads to loss of exons 2 and 3. (B) Diagrams of PGGV2-PGGV7 are depicted. Grey bars in PGGV5-7
represent unique insertion in LTR. The titer for each construct is shown to the right. SA, splice acceptor; LacZ, beta-galactosidase; Neo, neomycin
resistance marker; PolA, polyadenylation.
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 35-fold repression of F-luc was observed in the original
reporter cell line (59Z4) transfected with the F-luc
shRNA, whereas a dramatic loss of F-luc repression was
seen in several isolated mutants (Figure 3D). Thus, the
luciferase assay conﬁrmed that the isolated HAT
R clones
were truly RNAi-defective.
Identification of Ago2 mutants validates theutility of
thescreen
After conﬁrmation of the RNAi mutant phenotype by
luciferase assay, we performed Splinkerette PCR to
identify the gene trap integration site. Six independent
clones had gene trap integrations within the 38-kb
intron 1 of Ago2 (Figure 4A). Loss of Ago2 was conﬁrmed
by western blot on several of the mutants (Figure 4A).
Other clones, which were isolated once, included VIG
(by PGGV6), and CA150 (by PGGV7). To conﬁrm that
the Ago2 clones were indeed homozygous for the
gene trap, we performed Southern blot analysis. For
Ago2 clone #13, genomic DNA was digested with
EcoRI and hybridized with a probe detecting a region
ﬂanking the gene trap. Southern blot analysis showed
that the Ago2 mutant cells are homozygous for the gene
trap (Figure 4B). However, two other mutant clones
Figure 3. Conﬁrmation of RNAi mutants. (A) Methylene blue staining of viable cells showing the drug resistance of a putative RNAi mutant as
compared to the reporter cell line, 59Z4. (B) A Southern blot of EcoRI digested DNA using a probe unique to the gene trap identiﬁes distinct gene-
trap integration events by size. (C) Western and northern blots show that Hprt protein and RNA expression returns to levels similar to the parental
cell line, PGG5-4. For the western blot, b-tubulin is shown as a loading control. For the northern blot, the 28S and 18S rRNAs are shown as a
loading control. (D) A luciferase assay was used to conﬁrm that HAT
R clones are RNAi-defective. The fold repression of F-luc by the luc1-shRNA is
shown for the reporter (59Z4) and mutant cell lines. The data shown are the average of six independent luciferase assays, and error bars represent
the standard error of the mean. The F-luc data was normalized to R-luc and the fold repression of F-luc by the control shRNA was set to 1
(not plotted). The reporter cell line represses the F-luc reporter 35-fold while the mutants repress 1- to 2-fold.
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gene trap (data not shown). The signiﬁcance of these het-
erozygous gene trap clones remains to be determined.
Genetic rescue of Ago2 mutantES cells
To conﬁrm Ago2 is the cause of the RNAi mutant phe-
notype, we performed a genetic rescue with a human
Ago2 (hAgo2) transgene. A blasticidin (BSD)-linked
hemagglutinin-tagged hAgo2 (BSD-HA-hAgo2) transgene
was electroporated into the mutant cells and selected
with BSD (Figure 5A). Following BSD selection,
cells were selected with 6-TG to identify Hprt-silent rever-
tants (Figure 5B). Introduction of the hAgo2 transgene
was able to revert the HAT
R/6-TG
S phenotype to
the reporter HAT
S/6-TG
R phenotype (Figure 5B).
Western and northern analysis of Hprt levels conﬁrmed
that the Hprt gene was silenced in the rescued clones
(Figure 5C). The 6-TG
R clones of hAgo2 were pooled
and further analyzed by luciferase assay. The
hAgo2-rescued cells regained their ability to eﬃciently
silence the F-luc reporter as compared to the original
reporter cell line, 59Z4 (Figure 5D). Therefore, the
hAgo2 transgene rescued the RNAi defect in these cells.
Of the four mammalian Argonautes, Ago2 has been
shown to be the only Argonaute capable of performing
mRNA cleavage (26,27). In contrast, all mammalian
Argonautes are capable of binding miRNAs (26). To
test whether the Ago2 mutant would also show a defect
in the miRNA pathway, we performed a miRNA repres-
sion assay using a F-luc reporter with six miRNA binding
Figure 4. Isolation of Ago2 mutants. (A) All Ago2 gene-trap mutants were identiﬁed in the ﬁrst intron of the Ago2 locus, six are depicted in the
diagram with the gene trap construct that was used in the screen shown above the arrowheads. A western blot for Ago2 shows that endogenous
Ago2 was below detection in the mutant cells. (B) To conﬁrm that the isolated Ago2 mutant was homozygous for the gene trap, a Southern blot was
performed on EcoRI digested DNA from the reporter cell line and one of the Ago2 mutants, Ago2# 13. A probe for a region ﬂanking the Ago2 gene
trap was used to detect the wild-type locus as a 3.1kb fragment and the gene trap locus as a 5.7kb fragment. The Ago2 mutant is homozygous for
the gene trap as shown by the detection of only the 5.7kb fragment.
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exhibited only a mild reduction in miRNA repression
compared to the control cells (Figure 5E). This result cor-
roborates previous reports that Ago2 is essential for
siRNA-mediated target mRNA cleavage but not required
for miRNA mediated translational repression (26,27).
Mutations inthe Ago2 mid-domain disruptits cleavage
activity
The luciferase-reporter assay revealed that the homozy-
gous Ago2 gene trap cell line has a nearly complete loss
of RNAi-directed cleavage activity. Thus, these cells pro-
vide an Ago2 null genetic background to examine the
eﬀects of speciﬁc Ago2 mutations. The Ago2-deﬁcient
cell line also allows testing of genetic rescue by drug selec-
tion, as expression of wild-type hAgo2 reverted Ago2
mutant cells to 6-TG
R. An assay based on drug selectable
rescue in mutant cells would be useful for rapid structure–
function analysis of RNAi pathway components. To test
this possibility, we asked whether this method could be
used to resolve a controversy regarding Ago2 activity.
Ago2-F2V2 is an Ago2 mutant in which two highly
Figure 5. Rescue of the gene trap Ago2 mutant by a hAgo2 transgene. (A) Schematic of the hAgo2 rescue construct. (B) Rescue of the Ago2 mutant
reverts the drug resistance phenotype to HAT
S and 6-TG
R (compare to the drug resistance phenotype of the Ago2 mutant). (C) Rescue of the Ago2
mutant also reverts the levels of Hprt back to reporter cell (59Z4) levels as shown by northern and western blots. An Ago2 western blot performed
on parental (PGG5-4), reporter (59Z4), mutant and rescued cell lines showing similar levels of Ago2 in the rescued cells. (D) A luciferase assay for
RNAi-directed mRNA cleavage conﬁrms the rescue of Ago2 mutant by hAgo2 transgene. (E) A luciferase assay was used to examine miRNA
repression and shows that the Ago2 mutant exhibits a slight decrease in miRNA repression compared to the original reporter cell line 59Z4.
Calculations for data shown in (D) and (E) were performed as in Figure 3D.
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domain are mutated to valines. Recent reports on this
Ago2 mutant have had contradictory ﬁndings. One
group found that the Ago2-F2V2 mutations disable the
ability of hAgo2 to bind to m
7G caps, while they observed
no eﬀect on the ability of hAgo2-F2V2 to perform RNAi-
directed mRNA cleavage in an in vitro assay (28). A
second group discovered that the equivalent mutations
disrupt the ability of Drosophila Ago1 and Ago2 to repress
mRNA through a tethering assay, however they did not
observe a loss of binding ability to m
7G caps (29). The
F2V2 mutations could globally aﬀect the Ago2 protein,
which might account for the loss of translational repres-
sion observed in this mutant.
To further examine the eﬀect of the F2V2 mutation on
cleavage activity, we attempted genetic rescue of the
Ago2 mutant using the Ago2-F2V2 mutant. A BSD-
linked HA-tagged Ago2-F2V2 transgene (BSD-HA-
Ago2-F2V2) was electroporated into the Ago2 mutant
and cells were selected with BSD. For these studies,
BSD-linked HA-tagged constructs of the noncleavage
competent Argonautes (Ago1, 3 and 4) served as negative
controls and BSD-HA-hAgo2 served as a positive control
(Figure 6A). The transfected cells were selected with either
BSD alone or BSD with 6-TG. Only the hAgo2 construct
was capable of rescuing the Ago2 mutant cell line by 6-TG
selection (Figure 6A). A western blot for HA conﬁrms
that the levels of the BSD-HA-hAgo2 and BSD-HA-
hAgo2-F2V2 were comparable, demonstrating that the
lack of rescue was not due to a lower level of expression
of the hAgo2-F2V2 (Figure 6B). Consistent with drug
selection, western blots showed that only Ago2 could
repress the Hprt gene through a working RNAi pathway,
whereas Ago1, 3, 4 and Ago2-F2V2 were unable to do so
(Figure 6B). In addition, we performed an siRNA-based
luciferase assay to examine cleavage activity and did not
observe any ability of the Ago2-F2V2 mutant protein to
repress the luciferase reporter (Figure 6C). Thus, our data
Figure 6. Ago2 mutant ES cells can serve as a tool to perform mutational analysis. (A) The mutant Ago2 cell line was transfected with transgenes
expressing a BSD-linked, HA-tagged cDNA construct for Ago1, Ago2, Ago3, Ago4 and Ago2-F2V2. Cells were selected with BSD or BSD with
6-TG. Only stable transfection of WT-Ago2 can revert the 6-TG
S phenotype of the mutant cells. (B) Western blot for HA shows the expression levels
of diﬀerent Ago proteins. Western blot for Hprt shows that only Ago2 expression silences Hprt expression. Tubulin is shown as a loading control.
(C) A luciferase assay for RNAi-directed cleavage activity shows that Ago2-F2V2 is deﬁcient for cleavage activity. (D) Coimmunoprecipitation
performed in 293T cells shows that GFP-Ago2 is associated with Flag-tagged Ago2 as well as Flag-tagged Ago2-F2V2.
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strating that the F2V2 mutations may produce global
defects in Ago2’s function.
Previously, it was shown that immunoprecipitated
Ago2-F2V2 was capable of cleavage in vitro (28). In
order to rationalize the contradiction between our data
and this ﬁnding, we reasoned that the immunoprecipitated
Ago2-F2V2 might have also coimmunoprecipitated
WT-Ago2. To test this idea, we transfected 293T cells
with WT-GFP-Ago2 and either 3xFLAG-WT-Ago2 or
3xFLAG-Ago2-F2V2. Immunoprecipitation of Flag-
tagged Ago2 proteins revealed that both WT-Ago2
and Ago2-F2V2 were associated with WT-GFP-Ago2
(Figure 6D). Thus, the previous observation of cleavage
activity associated with Ago2-F2V2 may have been due to
the presence of coimmunoprecipitated endogenous Ago2.
Our ﬁnding that Ago2-F2V2 is deﬁcient in RNAi-directed
cleavage, together with the ﬁnding that F2V2 substitution
abolishes translational repression (29) suggests a critical
role of the mid-domain for overall function or structural
integrity of Ago2.
DISCUSSION
Key components of the RNAi pathway have been identi-
ﬁed through genetic screens in model organisms.
Performing a recessive genetic screen in a mammalian
system is feasible through the use of Blm-deﬁcient ES
cells. Here, we show the utility of screening for RNAi
components in Blm-deﬁcient cells by isolating an essential
component of RNAi, Ago2. Several Ago2 mutants were
isolated through our screen. One interpretation of this
result is that Ago2 is the most essential component for
siRNA-mediated RNAi. Interestingly, minimal RISC
has been shown to be composed solely of Ago2 and
siRNA (30). In addition, the identiﬁcation of six indepen-
dent Ago2 gene traps within intron 1 could indicate a hot
spot for retroviral integration. Consistent with this, a sim-
ilar Ago2 gene trap ES cell line was described in the gene
trap consortium (www.genetrap.org).
We found that Ago2 mutant ES cells display only a
slight defect in miRNA-mediated repression. In contrast,
the gene trap Ago2 mutants display a dramatic loss of
RNAi-directed cleavage activity. The nearly cleavage-deﬁ-
cient background of the Ago2 mutant provides a useful
tool to examine the cleavage activity of Ago2 proteins
with speciﬁc mutations. We transfected an Ago2 contain-
ing mid-domain mutations, Ago2-F2V2, into our Ago2
mutant cell line to assess the ability of Ago2-F2V2 to per-
form RNAi-directed cleavage. Through this method, we
have shown that the two mutations in the mid-domain of
Ago2 abolish cleavage activity. The recent crystal struc-
ture of the Thermus thermophilus Argonaute bound to a
guide-strand reveal that the 50-phosphate of the guide
strand is bound in a pocket in the mid-domain (31). It is
possible that the F2V2 mutations might have disrupted
the structural conformation of the binding pocket of the
mid-domain, thus disabling its ability to bind siRNA. Our
system can be further used to characterize the importance
of newly identiﬁed posttranscriptional modiﬁcations of
Ago2 on RNAi-directed cleavage activity (32,33).
Although this screen was successful in isolating Ago2,
there appears to be limitations of this system. For exam-
ple, the screen did not pull out other core components
of the RNAi pathway such as Dicer. One reason for this
could be the growth defect exhibited by Dicer
 /  ES cells
(34). Slower growing Dicer
 /  cells may be lost during
several passages of Blm-deﬁcient ES cells to create homo-
zygous mutations. The screen also identiﬁed heterozygous
gene traps, whose homologs have been identiﬁed in previ-
ous studies for RNAi components in other model systems.
VIG and CA150 have been isolated previously as RNAi
components (35–37). However, these clones were proven
to be heterozygous for their gene traps, thus making it
diﬃcult to determine whether they are the causative muta-
tions. One possible explanation for the gene trap hetero-
zygotes is the accumulation of point mutations in our
reporter cell lines over time. These point mutations may
rest on the sister allele of the gene trapped allele or a
completely independent mutation. The accumulation of
point mutations may be avoided by the use of an inducible
Blm-deﬁcient cell line to control the mutagenic rate of the
cells (21).
Improvements to our system can be implemented to
potentially identify more components of the RNAi path-
way. A new method to mutagenize ES cells, the Piggy-Bac
transposon, has recently been reported (38). Similar to
gene traps, the Piggy-Bac transposon can be molecularly
analyzed for the site of integration, and can potentially
circumvent the problems associated with the nonrandom
bias of retroviral gene trap mutagenesis. In addition,
transposons can be removed by expressing transposase,
facilitating analysis of revertants. Another way to improve
the screen might be to use a diﬀerent observable pheno-
type to select for RNAi mutants. For example, the screen
could be set up to detect RNAi mutants using a GFP
reporter combined with FACS analysis. The use of a dif-
ferent selectable phenotype has greatly improved other
screens for RNAi pathway genes. For instance, a screen
for RNAi components in C. elegans based on embryonic
lethality pulled out three genes (39). In contrast, a screen
in C.elegans based on silencing of GFP in seam cells led to
the identiﬁcation of 90 genes (35). Therefore, the use of
various selectable phenotypes can be advantageous for
pulling out more RNAi components.
Understanding the repertoire of mammalian RNAi
components has many potential beneﬁts. A new class of
endogenous siRNAs (endo-siRNAs) has recently been
identiﬁed in mice and ﬂies (40). A better understanding
of the mammalian RNAi pathway can help elucidate the
RNAi mechanism of these newly identiﬁed endo-siRNAs.
In addition, RNAi-based therapies can be improved by a
more comprehensive knowledge of the RNAi pathway in
a mammalian system. We have shown that a recessive
genetic screen for mammalian RNAi genes can be
performed in Blm-deﬁcient ES cells to pull out a key com-
ponent of the siRNA pathway. Therefore, with improve-
ments like a new insertional mutagenesis tool, the
transposon-mediated gene trap, this screening system has
e34 Nucleic Acids Research,2009, Vol. 37,No. 4 PAGE 10 OF11the potential to identify as-yet-unknown mammalian
RNAi components.
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